Government-Owned Inventions; Availability for Licensing, 14593-14594 [E7-5676]
Download as PDF
<![CDATA[
Federal Register / Vol. 72, No. 59 / Wednesday, March 28, 2007 / Notices
from this avian AAV are likely to find
novel applications for gene therapy in
humans. Furthermore because of their
species of origin, this vector would also
be useful in the engineering of avian
cells.
Inventors: Ioannis Bossis and John A.
Chiorini (NIDCR).
Publication: I Bossis, JA Chiorini.
Cloning of an avian adeno-associated
virus (AAAV) and generation of
recombinant AAAV particles. J Virol.
2003 Jun;77(12):6799–6810.
Patent Status: U.S. Patent Application
No. 10/557,662 filed 21 Dec 2006 (HHS
Reference No. E–105–2003/0–US–03).
Licensing Status: Available for nonexclusive or exclusive licensing.
Licensing Contact: Jesse S. Kindra,
J.D.; 301/435–5559;
kindraj@mail.nih.gov
Collaborative Research Opportunity:
The National Institute of Dental and
Craniofacial Research, Laboratory of Dr.
John Chiorini, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize gene therapy methods
using AAV vectors. Please contact David
W. Bradley, PhD at
bradleyda@nidcr.nih.gov for more
information.
sroberts on PROD1PC70 with NOTICES
Serotonin-Deficient Knock-Out Mouse
Description of Technology: Serotonin
is an important modulator of many
developmental, behavioral, and
physiological processes, and it has been
implicated in depression, anxiety,
schizophrenia, obsessive compulsive
disorders, and substance abuse.
Serotonin’s pharmacology is extremely
complex and it is mediated by seven of
serotonin receptor subtypes and it is
present in several tissues. Although it
has been a subject of a number of
studies, its role has been difficult to
ascertain. To investigate the role of
serotonin in these disorders, the murine
gene was disrupted by homologous
recombination. Results indicate that
serotonin binding sites were absent in
different brain regions (brain stem,
frontal cortex, hippocampus, and
striatum), and its concentrations were
reduced by 60–80%. These mice
represent a powerful tool for the
investigation of behavioral and
neuropsychiatric disorders, and
development of drug treatments for
these disorders.
Applications: A model to study
serotonin’s role in behavioral and
neuropsychiatric disorders.
Market:
1. Serotonin inhibitors are most
widely used treatment in
VerDate Aug<31>2005
17:09 Mar 27, 2007
Jkt 211001
neuropsychological disorders. Examples
include Zoloft, Paxil, and Prozac.
2. Depression effects approximately
18.8 million U.S. citizens and over 121
million people worldwide.
3. Antidepressant market was worth
$16.2 billion in 2005, and it has annual
growth of 2% year on year.
4. Anxiety disorders affect 40 million
(18.1%) of the adult U.S. population.
5. Global anxiety disorder market was
$4.5 billion in 2006.
Inventors: Dennis L. Murphy (NIMH)
et al.
Publications:
1. RF Ren-Patterson, LW Cochran, A
Holmes, S Sherrill, SJ Huang, T Tolliver,
K-P Lesch. Loss of brain-derived
neurotrophic factor gene allele
exacerbates brain monoamine
deficiencies and increases stress
abnormalities of serotonin transporter
knockout mice. J Neurosci Res. 2005
Mar 15:79(6):756–771.
2. DL Murphy, A Lerner, G Rudnick,
K-P Lesch. Serotonin transporter: gene,
genetic disorders, and
pharmacogenetics. Mol Interv. 2004
April:4(2):109–123.
3. RF Ren-Patterson, D-K Kim, X
Zheng, S Sherrill, S-J Huang, T Tolliver,
DL Murphy. Serotonergic-like
progenitor cells propagated from neural
stem cells in vitro: survival with SERT
protein expression following
implantation into brains of mice lacking
SERT. FASEB J. 2005 Sep:19(11):1537–
1539.
4. Q Li, A Holmes, L Ma, LD Van de
Kar, F Garcia, DL Murphy. Medical
hypothalamic 5-hydroxytryptamine
(5HT)1A receptors regulate
neuroendocrine responses to stress and
exploratory locomotor activity
application of recombinant adenovirus
containing 5-HT1A sequences. J
Neurosci. 2004 Dec 1:24(48):10868–
10877.
5. F Kilic, DL Murphy, G Rudnick. A
human serotonin transporter mutation
causes constitutive activation of
transport activity. Mol Pharmacol. 2003
Aug:64(2):440–446.
6. DL Murphy, GR Uhl, A Holmes, R
Ren-Patterson, FS Hall, I Sora, S DeteraWadleigh, K-P Lesch. Experimental gene
interaction studies with SERT mutant
mice as models for human polygenic
and epistatic traits and disorders. Genes
Brain Behav. 2003 Dec:2(6):350–364.
7. N Ozaki, D Goldman, WH Kaye, K
Plotnicov, BD Greenberg, J Lappalainen,
G Rudnick, DL Murphy. Serotonin
transporter missense mutation
associated with a complex
neuropsychiatric phenotype. Mol
Psychiatry. 2003 Nov:8(11):933–936.
Patent Status: HHS Reference No.
B–019–1999/0—Research Tool.
PO 00000
Frm 00079
Fmt 4703
Sfmt 4703
14593
Licensing Status: This technology is
available as a research tool under a
Biological Materials License.
Licensing Contact: Jennifer Wong;
301/435–4633; wongje@mail.nih.gov.
Dated: March 15, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E7–5675 Filed 3–27–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Microdialysis Probe for Accessing
Tissue in-vivo
Description of Technology: Available
for licensing and commercial
development is a microdialysis probe.
This device permits in-vivo
measurement of bioavailable substances
(e.g., cytokines, growth factors,
neuropeptides, inflammatory mediators,
etc.) at picogram levels of concentration
directly from soft tissue and organ
systems. The probe may also serve as an
in-situ drug delivery vehicle of micro
doses of medication to specific
anatomical sites by slow diffusion. It
also permits measurement of efficacy of
drug delivery, whether given orally,
systemically or topically, at the local
E:\FR\FM\28MRN1.SGM
28MRN1
14594
Federal Register / Vol. 72, No. 59 / Wednesday, March 28, 2007 / Notices
sroberts on PROD1PC70 with NOTICES
tissue level. It can be utilized in a
variety of patient populations and
conditions. For example, the probe can
be used to monitor the local
biochemical milieu in soft tissue and
organ systems to provide insights into
the pathophysiology of musculoskeletal,
neuromuscular, rheumatic,
gastrointestinal, renal, cardiovascular
and endocrinologic diseases, cancers,
dermatological conditions, and pediatric
disorders, especially in premature
newborns.
The probe is made from a small-bore
(32 gauge) needle, whose probe surface
has been fashioned to permit near
trauma-less entry, containing both a
fluid delivery and recovery tube within
the bore. A molecular exchange
membrane is positioned about 200
microns from the tip. Fluid flows across
the membrane removing diffused
molecules to a collection device. The
rounded tip of the needle is designed to
cause minimal tissue damage while
allowing investigations to be performed
on local tissue fluids. Additionally, this
device allows simultaneous delivery of
small concentrations of drug. In
summary, this unique apparatus
provides a minimally invasive means
for sampling biological fluids in any
human or animal organ or tissue and for
in-situ drug-delivery, in continuous or
incremental dosing, of extremely small
doses.
Applications: Measurement of
bioavailable substances in organs and
soft tissues; Localized drug delivery
vehicle; Measurement of tissue drug
levels.
Market: Drug discovery; Tissue/fluid
sampling; Pain management.
Inventors: Jay Shah (NIHCC), Terence
Martyn Phillips (ORS), Jerome V. Danoff
(NIHCC), Lynn Gerber (NIHCC).
Publication: JP Shah, TM Phillips, JV
Danoff, LH Gerber. An in vivo
microanalytical technique for measuring
the local biochemical milieu of human
skeletal muscle. J Appl Physiol. 2005
Nov; 99(5):1977–1984. Epub 2005 Jul
21.
Patent Status: U.S. Provisional
Application No. 60/795,176 filed 27 Apr
2006 (HHS Reference No. E–024–2006/
0–US–01).
Licensing Contact: Michael A.
Shmilovich, Esq.; 301/435–5019;
shmilovm@mail.nih.gov.
Fluorescent Intracellular Calcium
Indicators
Description of Technology: Calcium is
a key element in the regulation of many
cellular processes, including muscle
contraction, hormone excretion from
gland cells, neurotransmitter release
from nerve synapses, and the regulation
VerDate Aug<31>2005
17:09 Mar 27, 2007
Jkt 211001
of cellular metabolism. Elevated
calcium levels are found in a number of
diseases.
The present invention relates to
chromophoric or fluorescent dye
calcium indicators that are superior for
measurement of high concentrations of
calcium ions due to their high
dissociation constants. As a result of the
high calcium ion dissociation constants,
the perturbation resulting from
introducing the indicator into the cell is
greatly reduced. These calcium ion
indicators can be measured by various
techniques including 19F NMR
spectroscopy, flow cytometry, and
quantitative fluorescence techniques,
and are useful for measuring calcium
levels within the cytosol or within
cellular organelles.
Application: Research tool for
quantifying intracellular calcium
concentrations.
Inventors: Robert E. London, Louis A.
Levy, and Elizabeth Murphy (NIEHS).
Patent Status: U.S. Patent Application
No. 08/175,590 filed 30 Dec 1993,
which issued as U.S. Patent No.
5,516,911 on 14 May 1996 (HHS
Reference No. E–015–1993/0–US–01).
Licensing Status: Available for
nonexclusive licensing.
Licensing Contact: Tara Kirby, PhD;
301/435–4426; tarak@mail.nih.gov.
Collaborative Research Opportunity:
The NIEHS Laboratory of Structural
Biology is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize this technology. Please
contact Dr. Robert London at 919/541–
4879 or london@niehs.nih.gov for more
information.
Dated: March 19, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E7–5676 Filed 3–27–07; 8:45 am]
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center on
Minority Health and Health Disparities
Special Emphasis Panel, LRP for Health
Disparities and Clinical Research-Panel B.
Date: April 29, 2007.
Time: 9 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6707
Democracy Blvd./Suite 800, Bethesda, MD
20892, (Virtual Meeting).
Contact Person: Lorrita Watson, PhD,
National Center on Minority Health, and
Health Disparities, National Institutes of
Health, 6707 Democracy Blvd., Suite 800,
Bethesda, MD 20892–5465, (301) 402–1366,
watsonl@ncmhd.nih.gov.
Name of Committee: National Center on
Minority Health and Health Disparities
Special Emphasis Panel, NCMHD Conference
Grant Application (R13) Review.
Date: May 1, 2007.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Virtual
Meeting).
Contact Person: Robert Nettey, MD,
Scientific Review Administrator, National
Institute on Minority Health, and Health
Disparities, 6707 Democracy Blvd., Suite 800,
Bethesda, MD 20892, 301–496–3996.
Dated: March 21, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–1516 Filed 3–27–07; 8:45 am]
BILLING CODE 4140–01–M
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
National Center on Minority Health and
Health Disparities; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
PO 00000
Frm 00080
Fmt 4703
Sfmt 4703
National Eye Institute, Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
E:\FR\FM\28MRN1.SGM
28MRN1
]]>Agencies
[Federal Register Volume 72, Number 59 (Wednesday, March 28, 2007)]
[Notices]
[Pages 14593-14594]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-5676]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Microdialysis Probe for Accessing Tissue in-vivo
Description of Technology: Available for licensing and commercial
development is a microdialysis probe. This device permits in-vivo
measurement of bioavailable substances (e.g., cytokines, growth
factors, neuropeptides, inflammatory mediators, etc.) at picogram
levels of concentration directly from soft tissue and organ systems.
The probe may also serve as an in-situ drug delivery vehicle of micro
doses of medication to specific anatomical sites by slow diffusion. It
also permits measurement of efficacy of drug delivery, whether given
orally, systemically or topically, at the local
[[Page 14594]]
tissue level. It can be utilized in a variety of patient populations
and conditions. For example, the probe can be used to monitor the local
biochemical milieu in soft tissue and organ systems to provide insights
into the pathophysiology of musculoskeletal, neuromuscular, rheumatic,
gastrointestinal, renal, cardiovascular and endocrinologic diseases,
cancers, dermatological conditions, and pediatric disorders, especially
in premature newborns.
The probe is made from a small-bore (32 gauge) needle, whose probe
surface has been fashioned to permit near trauma-less entry, containing
both a fluid delivery and recovery tube within the bore. A molecular
exchange membrane is positioned about 200 microns from the tip. Fluid
flows across the membrane removing diffused molecules to a collection
device. The rounded tip of the needle is designed to cause minimal
tissue damage while allowing investigations to be performed on local
tissue fluids. Additionally, this device allows simultaneous delivery
of small concentrations of drug. In summary, this unique apparatus
provides a minimally invasive means for sampling biological fluids in
any human or animal organ or tissue and for in-situ drug-delivery, in
continuous or incremental dosing, of extremely small doses.
Applications: Measurement of bioavailable substances in organs and
soft tissues; Localized drug delivery vehicle; Measurement of tissue
drug levels.
Market: Drug discovery; Tissue/fluid sampling; Pain management.
Inventors: Jay Shah (NIHCC), Terence Martyn Phillips (ORS), Jerome
V. Danoff (NIHCC), Lynn Gerber (NIHCC).
Publication: JP Shah, TM Phillips, JV Danoff, LH Gerber. An in vivo
microanalytical technique for measuring the local biochemical milieu of
human skeletal muscle. J Appl Physiol. 2005 Nov; 99(5):1977-1984. Epub
2005 Jul 21.
Patent Status: U.S. Provisional Application No. 60/795,176 filed 27
Apr 2006 (HHS Reference No. E-024-2006/0-US-01).
Licensing Contact: Michael A. Shmilovich, Esq.; 301/435-5019;
shmilovm@mail.nih.gov.
Fluorescent Intracellular Calcium Indicators
Description of Technology: Calcium is a key element in the
regulation of many cellular processes, including muscle contraction,
hormone excretion from gland cells, neurotransmitter release from nerve
synapses, and the regulation of cellular metabolism. Elevated calcium
levels are found in a number of diseases.
The present invention relates to chromophoric or fluorescent dye
calcium indicators that are superior for measurement of high
concentrations of calcium ions due to their high dissociation
constants. As a result of the high calcium ion dissociation constants,
the perturbation resulting from introducing the indicator into the cell
is greatly reduced. These calcium ion indicators can be measured by
various techniques including 19F NMR spectroscopy, flow cytometry, and
quantitative fluorescence techniques, and are useful for measuring
calcium levels within the cytosol or within cellular organelles.
Application: Research tool for quantifying intracellular calcium
concentrations.
Inventors: Robert E. London, Louis A. Levy, and Elizabeth Murphy
(NIEHS).
Patent Status: U.S. Patent Application No. 08/175,590 filed 30 Dec
1993, which issued as U.S. Patent No. 5,516,911 on 14 May 1996 (HHS
Reference No. E-015-1993/0-US-01).
Licensing Status: Available for nonexclusive licensing.
Licensing Contact: Tara Kirby, PhD; 301/435-4426;
tarak@mail.nih.gov.
Collaborative Research Opportunity: The NIEHS Laboratory of
Structural Biology is seeking statements of capability or interest from
parties interested in collaborative research to further develop,
evaluate, or commercialize this technology. Please contact Dr. Robert
London at 919/541-4879 or london@niehs.nih.gov for more information.
Dated: March 19, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E7-5676 Filed 3-27-07; 8:45 am]
BILLING CODE 4140-01-P
